胃癌细胞的体外药敏试验与多药耐药基因表达的关系  

Relationship between Chemosensitivity in Vitro and Multidrug Resistance Gene Expression in Gastric Cancer

作　　者：赵蓉[1] 贾荣娣[1] 汪华君[1] 王旭青[1] 张九如[1] 

机构地区：[1]江苏大学附属医院,江苏镇江212001

出　　处：《抗感染药学》2012年第4期297-301,共5页Anti-infection Pharmacy

基　　金：江苏大学医学临床科技发展基金资助项目(编号:JLY2010162)

摘　　要：目的:分析胃癌细胞的体外药敏试验与多药耐药基因的表达之间的相关性。方法:采用MTT法测定化疗药物对胃癌肿瘤细胞的敏感性;用逆转录聚合酶链反应(RT-PCR)测定胃癌组织中多药耐药基因(MDR1,MRP1,ABCG2,Topo-2mRNA)的表达水平。结果:单药组抑制率最高为5-FU(36.51%),联合用药组抑制率最高为DCF(56.80%);多药耐药基因(MDR1,MRP1,ABCG2,Topo-2mRNA在胃癌组织中的阳性率分别为33.3%,42.9%,52.4%,66.7%。结论:体外药敏试验测定并结合多药耐药基因表达的相关性可提高预测肿瘤的敏感性或发现其耐药性,为临床实现个体化治疗提供参考依据。Objective： To study the correlation between chemotherapy drug sensitivity in vitro and the mRNA expression of multidrug resistance genes in gastric cancer. Methods： The chemotherapy drug sensitivity in vitro was evaluated by MTT and the mRNA expression of MDR1, MRP1, ABCG2 and Topo-2 in gastric cancer were detected by RT-PCR. Results： The single chemotherapy drug sensitivity order rate was 5-FU （36.51%）and combined chemotherapy drug sensitivity order rate was DCF（56.80%）. The positive rates of MDR1, MRPI, ABCG2 and Topo-2 mRNA were 33.3%, 42.9%, 52.4% and 66.7% respectively. Conclusion： In vitro drug sensitivity determination of binding and the relationship between the expression of multidrug resistance genecan improve the prediction of tumor sensitivity and find out the possibility of drug resistance for Implementation of individualized therapy for clinical reference.

关 键 词：胃癌 多药耐药基因 关系 

分 类 号：R969.3[医药卫生—药理学]